|
Myasthenia Gravis Research Highlights: AAN 2023
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria... |
|
|
COVID-19 Vaccine Myth Busters (Technician)
Recommendations regarding COVID-19 immunizations are being updated frequently. This session will discuss the safety and efficacy data available for the COVID-19 vaccines that have received an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). Included in the discussion will be the mechanism of action and a comparison of dosage, schedule, and storage for the available COVID-19 vaccines. Patient cases to review recommended vaccines based on patient-specific factors an... |
|
|
COVID-19 Vaccine Myth Busters (Pharmacist)
Recommendations regarding COVID-19 immunizations are being updated frequently. This session will discuss the safety and efficacy data available for the COVID-19 vaccines that have received an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). Included in the discussion will be the mechanism of action and a comparison of dosage, schedule, and storage for the available COVID-19 vaccines. Patient cases to review recommended vaccines based on patient-specific factors an... |
|
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
|
INFORM: Information Needed for Optimal Regulation of Mycophenolate- A REMS Activity
Target Audience
The target audience for this initiative includes obstetricians, gynecologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and care team members involved in the treatment of women across their reproductive lifespan who may have been prescribed mycophenolate products.
Program Overview
Clinicians who work with women of childbearing age who are, or will be, taking mycophenolate must ensure that their patients receive appropriate counseling... |
|
|
Case Challenges in nAMD and DME Management: Achieving Durable Response
The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni... |
|
|
Dental CE Online | 25 Credit Hours for $99 all 50 states | Dentists, Hygienists, Assistants - Instant Online Certificate | AGD PACE nationally approved
25 CE (CEU) credit hours: Custom packages available. For course substitutions, email us your desired course changes. Questions? Email: CEsupport@mydentalce.com or call (530) 238-5333. Fast & friendly customer service. Nationally approved provider Academy of General Dentistry 373218
ALL PACKAGE COURSES updated for 2022
*courses subject to change:
Infection Control OSHA Focus - 2 credit hours (2 CE)
OSHA Bloodborne Pathogens Standard Annual Review - 2 credit hours (2 CE)
OSHA Hazar... |
|
|
WEBINAR BUNDLE: Quality Compounding Summit Bundle
Earn up to 9 hours of continuing education focused on quality issues in compounding when you purchase the Quality Compounding Summit Bundle.
Session 1: NABP Implementation of the FDA Compounding MOU
Session 2: Pharmacist / Provider / Patient Triad: A Multidisciplinary Approach to Patient Care
Session 3: Quality Compounding and Clinical Pharmaceuticals
Session 4: Regulatory and Quality Considerations in the Selection of Active Pharmaceutical Ingredients
Session 5: Root C... |
|
|
Quality Compounding Summit: On-Demand
Earn up to 9 hours of continuing education focused on quality issues in compounding when you purchase the 2021 Quality Compounding Summit Bundle originally presented November 5-6, 2021.
Quality Compounding Summit 2021 Bundle - only $450
CE Session #1 - NABP Implementation of the FDA Compounding MOU
CE Session #2 - Pharmacist / Provider / Patient Triad: A Multidisciplinary Approach to Patient Care
CE Session #3 - Quality Compounding and Clinical Pharmaceuticals
CE Session #4 ... |
|
|
Recognition and Referral: Best Practices for Managing Patients with GA
Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ... |
|
|
Ohio Dental Radiography Review for Dental Assistants 2023-24 | 2 CEs Updated | Certificate Renewal & all 50 states | AGD PACE recognized provider | Affordable & Fast
Ohio Radiography Review for Dental Assistants (Ohio for certificate renewal). Take MyDentalCE.com online review course and get an instant certificate upon completion. This updated for 2022-24 Radiography Review for dental assistants is designed for the license renewal board requirements in Ohio as well as any other state in the US. This online radiography course includes 2023-24 updates, like new FDA safety guidelines, more details about digital imaging, and current information for all related... |
|
|
Dental Radiography Review for Dental Assistants 2023-24 | 2 CEs Updated - Includes Ohio radiographers certificate renewal & all 50 states | AGD PACE recognized provider | Affordable & Fast
Radiography Review for Dental Assistants (includes Ohio for certificate renewal). Take MyDentalCE.com online review course and get an instant certificate upon completion. This updated for 2023-24 Radiography Review for dental assistants is designed for the license renewal board requirements in Ohio as well as any other state in the US. This online radiography course includes 2023-24 updates, like new FDA safety guidelines, more details about digital imaging, more interactive media, and current... |
|
|
FOCUS: Functional pain and Opiods " Clinically Useful Strategies
Target Audience
The target audience includes family medicine physicians, emergency physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare providers involved in the management of patients experiencing functional pain
Program Overview
Learn how to assess and treat functional pain syndromes caused by nociplastic pain. This course is based on the FDA’s Opioid Analgesic REMS Education Blueprint.
Learning Objectives
Upon completion of this activity, parti... |
|
|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |
|
|
WEBINAR BUNDLE: Compounding Clarity: Decoding USP Standards in Pharmacy Practice Bundle
The Compounding Clarity: Decoding USP Standards in Pharmacy Practice bundle is accredited for 3.0 contact hours (0.3 CEUs) of continuing education credit for pharmacists and pharmacy technicians.
Webinar 1 - GFI #256: How it affects compounding for veterinary patients (2023)
This webinar will help veterinary compounders understand the requirements of GFI-256 and why such a document is necessary in the current federal landscape. Pharmacists and technicians will learn when FDA intends... |
|
|
WEBINAR: Legal Insights into Peptide & Semaglutide Compounding: Navigating FDA, State Boards, and Telemedicine
As the landscape of compounding peptides and semaglutide continues to evolve rapidly, a multitude of legal challenges and opportunities arise. This session aims to shed light on the pivotal developments and regulatory nuances in this dynamic sector.
Our speakers will delve into critical topics such as the FDA's current stance on peptide compounding, recent pronouncements from state Boards of Pharmacy, and the intricate legalities surrounding brand manufacturers. Additionally, the webi... |
|
|
Webinar - Pregabalin for Felines
Overview " Transportation anxiety is common in felines and can prevent owners from providing optimal care due to the stress and complications of simply getting to the veterinarian. Human pregabalin, alprazolam, and trazadone are some of the current options prescribed to pet owners to help, but pregabalin has been recently FDA-approved for this use in felines only to provide pet owners an easier time taking care of their loved one that has been studied and researched in felines specificall... |
|
|
Therapy Tidbits Summer 2021
Therapy Tidbits – Summer 2021 is a 1-hour online continuing education (CE) course comprised of select articles from the Summer 2021 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are:
• Improving Health through Community Policies Gains Momentum – Provides an overview of the Blue Zone Project and the impact on community members’ health.
• Psychologis... |
|